C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)

DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER...

MEXC Earn Achieves Dual-Scale Growth in 2025: 64% Users, 43% AUM

MEXC Earn Achieves Dual-Scale Growth in 2025: 64% Users, 43% AUM

VICTORIA, Seychelles, March 9, 2026 /PRNewswire/ -- MEXC, the world's fastest-growing digital asset exchange and a pioneer of true zero-fee trading, announced that its MEXC Earn platform achieved a 64% increase in users and a 43% growth in assets...

menu
menu